Cutamesine
Cutamesine is an experimental drug that was initially developed by Serono, a biopharmaceutical company. It is a synthetic compound that acts as a sigma-1 receptor agonist. The sigma-1 receptor is a chaperone protein that has been implicated in many diseases, including neurodegenerative diseases, cancer, and cardiovascular diseases. Cutamesine has been studied in clinical trials for the treatment of major depressive disorder, post-traumatic stress disorder, and Alzheimer's disease.
History[edit | edit source]
Cutamesine was first synthesized by Serono in the late 1990s. The company conducted initial preclinical studies and found that the compound had potential therapeutic effects in models of neurodegenerative diseases. In 2002, Serono initiated a Phase I clinical trial to evaluate the safety and tolerability of cutamesine in healthy volunteers.
Mechanism of Action[edit | edit source]
Cutamesine acts as an agonist at the sigma-1 receptor, a protein that is widely expressed in the body and has been implicated in a variety of diseases. The sigma-1 receptor is thought to play a role in the regulation of cell survival, neuroplasticity, and neuroprotection. By activating the sigma-1 receptor, cutamesine may help to protect neurons from damage and promote their survival.
Clinical Trials[edit | edit source]
Several clinical trials have been conducted to evaluate the efficacy of cutamesine in various diseases. In a Phase II trial for major depressive disorder, cutamesine was found to have a similar efficacy to a commonly used antidepressant, but with fewer side effects. However, a subsequent Phase III trial did not meet its primary endpoint, and the development of cutamesine for this indication was discontinued.
Cutamesine has also been studied in a Phase II trial for post-traumatic stress disorder. The results of this trial have not yet been published.
In addition, a Phase II trial of cutamesine in patients with Alzheimer's disease is currently ongoing. This trial is evaluating the safety and efficacy of cutamesine in slowing the progression of the disease.
Future Directions[edit | edit source]
The future development of cutamesine will depend on the results of ongoing clinical trials. If these trials demonstrate that cutamesine is safe and effective, it could potentially be approved for the treatment of Alzheimer's disease or other neurodegenerative diseases.
| Cutamesine Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
